Juno Therapeutics is a biopharmaceutical company developing medicines for the treatment of serious diseases.
Juno Therapeutics is a biopharmaceutical company focused on the development of clinical stage medicines for the treatment of serious diseases. The company was founded by Isabelle Rivière, Michael JensenMichael Jensen and Michel Sadelain in 2013 in Seattle, Washington, and was acquired by Celgene in January 2018.